Flash Finance

Divi's Laboratories LimitedDIVISLABCorporate

Healthcare Drug Manufacturers - Specialty & Generic Latest results: Jun 2026 15 quarters of data
Consolidated Standalone
₹9,144.50
MCap ₹242,758 Cr · P/E 83.0
Divi's Laboratories Limited — Stock analysis & AI research Divi's Laboratories Limited — Seasonality — best & worst months Divi's Laboratories Limited — Technical indicators & charts Divi's Laboratories Limited — Technical setup — score, trend, support & resistance Divi's Laboratories Limited — Live exchange announcements
📋 High ROCE Stocks📋 High Operating Margin Stocks📋 High Interest Coverage Stocks📋 Stocks With Strong Quarterly Results📋 Low Debt Stocks📋 Large Cap Stocks List 📈 SuperTrend Bearish Signal📈 Multi-Timeframe Bullish Stocks ⚖️ vs Neuland Laboratories⚖️ vs Jubilant Pharmova 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹3,080 Cr
Sales · Jun 2026
+27.8% YoY
₹1,255 Cr
Operating Profit · Jun 2026
+72.2% YoY
40.7%
OPM % · Jun 2026
+34.8% YoY
₹902 Cr
Net Profit · Jun 2026
+65.5% YoY
₹33.95
EPS · Jun 2026
+65.4% YoY

📝 Divi's Laboratories Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Divi's Laboratories Limited reported revenue of ₹3,080 crore for the quarter ended June 2026 (Q1 FY27), up 27.8% from ₹2,410 crore in the same quarter last year, and up 8.8% sequentially over the March 2026 quarter.

Net profit rose 65.5% year-on-year to ₹902 crore, from ₹545 crore. Earnings per share (EPS) came in at ₹33.95.

Operating profit stood at ₹1,255 crore — an operating margin (OPM) of 40.7%, compared with 30.2% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Divi's Laboratories Limited posted revenue of ₹10,560 crore, a growth of 12.8% over FY25, with a net profit of ₹2,568 crore (up 16.7% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹11,230 crore with a net profit of ₹2,925 crore.

Valuation snapshot

At the current price of ₹9,144.50, DIVISLAB has a market capitalisation of ₹242,758 crore and a trailing P/E of about 83.0.

Within the Drug Manufacturers - Specialty & Generic industry, it is the 2nd-largest of the 31 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 51.88%, foreign institutional investors (FIIs) 20.38%, domestic institutional investors (DIIs) 19.17%, public shareholders 8.58% of Divi's Laboratories Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹242,758 Cr
Current Price ?
₹9,144.5
P/E ?
82.99above ind
Industry P/E ?
35.00
P/B ?
14.48
P/S ?
21.62
P/FCF ?
1,098.45
Enterprise Value ?
₹242,765 Cr
EV/EBITDA ?
61.20
PEG ?
6.38
Earnings Yield ?
1.4%
Dividend Yield ?
0.32%
Profitability & Returns
Sales (TTM) ?
₹11,230 Cr
OPM ?
35.3%
Profit after tax (TTM) ?
₹2,925 Cr
EPS (TTM) ?
₹110.18
ROCE ?
22.0%
ROE ?
17.5%
ROA ?
14.6%
Growth
Sales — latest qtr ?
₹3,080 Cr
PAT — latest qtr ?
₹902 Cr
YoY qtr sales growth ?
27.8%
YoY qtr profit growth ?
65.5%
Sales growth (3y) ?
11%
Sales growth (5y) ?
9%
Profit growth (3y) ?
13%
Profit growth (5y) ?
6%
Financial Health
Debt ?
₹7 Cr
Debt to Equity ?
0.00
Interest Coverage ?
129.5
Current Ratio ?
N/A
Ownership
Promoter holding ?
51.88%
Change in promoter holding ?
0.00%
Pledged percentage ?
N/A
Market
Return 3 months ?
26.2%
Return 6 months ?
46.8%

🗓️ Quarterly results (15 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 1,6901,9511,7781,9091,8552,3032,1182,3382,3192,5852,4102,7152,6042,8313,080 +27.8% +8.8%
Operating Profit 4094885044794897316227167438867298888909341,255 +72.2% +34.4%
Other Income 11666818695797910682861191451415564 -46.2% -58.7%
Interest 000102010138666 +100.0% +0.0%
Depreciation 878793959595979999107112113118120133 +18.8% +10.8%
Profit Before Tax 4394664924694897136047227308617339127809631,180 +61.0% +22.5%
Net Profit 311321356348358538430510594667545689583751902 +65.5% +20.1%
EPS 11.7112.0913.4113.1113.4920.2516.2019.2122.1924.9420.5325.9521.9628.2933.95 +65.4% +20.0%
OPM % 24.2% 25.0% 28.3% 25.1% 26.4% 31.7% 29.4% 30.6% 32.0% 34.3% 30.2% 32.7% 34.2% 33.0% 40.7% +34.8% +23.3%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹9,360 Cr ₹10,560 Cr ₹11,230 Cr +12.8%
Operating Profit ₹2,967 Cr ₹3,441 Cr ₹3,967 Cr +16.0%
OPM % 31.70% 32.59% 35.33% +2.8%
NPM % 23.51% 24.32% 26.05% +3.4%
Other Income ₹353 Cr ₹433 Cr ₹378 Cr +22.7%
Depreciation ₹402 Cr ₹463 Cr ₹484 Cr +15.2%
Interest ₹2 Cr ₹23 Cr ₹26 Cr +1050.0%
EBIT ₹2,565 Cr ₹2,978 Cr ₹3,483 Cr +16.1%
PBT ₹2,917 Cr ₹3,388 Cr ₹3,835 Cr +16.1%
Tax — — ₹278 Cr —
Net Profit ₹2,201 Cr ₹2,568 Cr ₹2,925 Cr +16.7%
EPS ₹82.54 ₹96.73 ₹110.15 +17.2%
Material Cost — — ₹1,503 Cr —
Employee Cost — — ₹408 Cr —
Extraordinary Items — — — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 53535353 +0.0%
Reserves 12,71413,51814,91616,708 +12.0%
Borrowings 3347 +75.0%
Other Liabilities 1,6541,8861,9483,265 +67.6%
Total Liabilities 14,42515,46016,92120,033 +18.4%
Fixed Assets 4,7234,7395,4426,528 +20.0%
CWIP 2127781,0222,113 +106.8%
Investments 77826569 +6.2%
Other Assets 9,4139,86110,39211,323 +9.0%
Total Assets 14,42515,46016,92120,033 +18.4%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 2,4601,2611,6532,738 +65.6%
Cash from Investing Activity -2,708-269-804-2,219 -176.0%
Cash from Financing Activity -797-799-799-804 -0.6%
Net Cash Flow -1,04519350-285 -670.0%
Free Cash Flow 1,987258215221 +2.8%
CFO/OP 124%74%83%105% +26.5%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 84100106103 -2.8%
Inventory Days 352364311353 +13.5%
Days Payable 899488108 +22.7%
Cash Conversion Cycle 347370330348 +5.5%
Working Capital Days 188206192195 +1.6%
ROCE % 19%16%20%22% +10.0%

👥 Shareholding (latest 5 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Sep 2026 % Chg
Promoters 51.88%51.88%51.88%51.88%51.88% +0.0%
FIIs 19.74%19.39%20.08%20.29%20.38% +0.4%
DIIs 18.96%19.68%19.18%19.13%19.17% +0.2%
Government 0.09%0.09%0.09%0.09%— —
Public 9.32%8.96%8.75%8.61%8.58% -0.3%
No. of Shareholders 2,59,8252,49,6342,33,8442,28,0062,32,256 +1.9%

⚖️ Peer comparison

Industry: Drug Manufacturers - Specialty & Generic · top 25 of 31 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 SUNPHARMA Sun Pharmaceutical ₹1,840.00 441,478 36.5 59,911 12,104 29.8% 20.2% 11.2% 5.1% 10.5% 27.0%
2 DIVISLAB Divi's Laboratories ₹9,235.00 245,160 83.8 11,230 2,925 35.3% 26.0% 12.8% 16.7% 27.8% 65.5%
3 TORNTPHARM Torrent Pharmaceuticals ₹4,931.00 187,559 87.1 15,723 2,156 33.0% 13.7% 21.4% 11.9% 54.8% 3.3%
4 ZYDUSLIFE Zydus Lifesciences ₹1,162.20 115,930 23.2 27,148 5,070 31.2% 18.7% 16.8% 12.0% 16.2% 14.5%
5 CIPLA Cipla ₹1,366.00 110,353 32.7 28,324 3,356 18.7% 11.8% 2.2% -26.7% 2.3% -39.2%
6 LAURUSLABS Laurus Labs ₹1,969.00 106,387 97.2 7,270 1,090 28.0% 15.0% 22.7% 147.9% 29.1% 123.9%
7 DRREDDY Dr. Reddy's ₹1,165.50 97,085 29.3 28,704 3,273 15.3% 11.4% -10.4% -25.8% -5.6% -69.2%
8 AUROPHARMA Aurobindo Pharma ₹1,679.80 96,652 26.2 34,935 3,711 20.3% 10.6% 6.1% 0.6% 16.3% 25.2%
9 LUPIN Lupin ₹2,095.00 95,797 17.9 27,958 5,356 31.5% 19.2% 23.1% 62.0% 31.9% 87.8%
10 MANKIND Mankind Pharma ₹2,280.00 94,174 46.1 14,738 2,067 26.0% 14.0% 16.3% -3.7% 12.9% 29.1%
11 GLENMARK Glenmark Pharmaceuticals ₹2,419.20 68,276 38.0 17,737 1,797 27.0% 10.1% -61.2% -67.4% 23.1% 927.9%
12 ALKEM Alkem Laboratories ₹5,243.50 62,694 29.1 15,081 2,187 20.1% 14.5% 13.5% 7.6% 10.9% -21.6%
13 ABBOTINDIA Abbott India ₹25,860.00 54,951 34.0 7,005 1,615 28.1% 23.1% 8.1% 9.7% 4.4% 17.2%
14 IPCALAB Ipca Laboratories ₹1,964.20 49,833 38.0 10,125 1,379 22.0% 13.6% 7.9% 55.0% 20.8% 82.2%
15 GLAND Gland Pharma ₹2,935.90 48,433 47.1 6,431 1,028 25.3% 16.0% -64.7% -48.4% 22.3% 96.7%
16 AJANTPHARM Ajanta Pharma ₹3,398.90 42,472 37.4 5,777 1,135 25.4% 19.7% 17.3% 14.8% 24.8% 30.9%
17 JBCHEPHARM J. B. ₹2,416.10 38,793 53.4 4,148 709 26.7% 17.1% 5.9% 7.5% -4.8% -30.7%
18 EMCURE EMCURE PHARMACEUTICALS ₹1,975.10 37,470 37.0 9,684 1,019 20.4% 10.5% 16.6% 33.1% 22.8% 36.0%
19 WOCKPHARMA Wockhardt ₹2,021.50 32,848 92.5 3,133 353 19.9% 11.3% -2.3% 342.1% 25.9% 199.1%
20 NEULANDLAB Neuland Laboratories ₹23,455.00 30,093 82.7 2,023 365 28.4% 18.0% 37.0% 40.2% 136.3% 666.0%
21 PPLPHARMA Piramal Pharma ₹211.50 28,024 113.5 9,206 247 11.0% 2.7% -3.1% -37.9% 17.4% -161.3%
22 GRANULES Granules India ₹885.60 21,945 32.8 5,633 663 22.7% 11.8% 19.7% 18.8% 22.0% 59.3%
23 CAPLIPOINT Caplin Point ₹2,752.60 20,923 31.4 2,287 678 34.8% 29.7% 12.9% 20.2% 19.6% 18.8%
24 ERIS Eris Lifesciences ₹1,358.00 18,820 29.0 3,230 666 35.2% 20.6% 8.2% 72.6% 13.0% 14.6%
25 ASTRAZEN AstraZeneca Pharma ₹6,755.00 16,888 99.6 2,432 170 9.4% 7.0% 32.7% 62.1% 29.7% -32.1%
❓ Frequently asked questions
What was Divi's Laboratories Limited's revenue in Q1 FY27?
Divi's Laboratories Limited reported revenue of ₹3,080 crore for the quarter ended June 2026 (Q1 FY27), up 27.8% from ₹2,410 crore in the same quarter last year, and up 8.8% sequentially over the March 2026 quarter.
What was Divi's Laboratories Limited's net profit in Q1 FY27?
Net profit rose 65.5% year-on-year to ₹902 crore, from ₹545 crore. Earnings per share (EPS) came in at ₹33.95.
What is DIVISLAB's market capitalisation and P/E ratio?
At the current price of ₹9,144.50, DIVISLAB has a market capitalisation of ₹242,758 crore and a trailing P/E of about 83.0.
Who owns Divi's Laboratories Limited? (shareholding pattern)
As of Sep 2026, promoters held 51.88%, foreign institutional investors (FIIs) 20.38%, domestic institutional investors (DIIs) 19.17%, public shareholders 8.58% of Divi's Laboratories Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI